和信综字 (2025) 第 000229 号 llen 关于对山东鲁抗医药股份有限公司 2024 年年度报告的事后审核问询函的回复 和信会计师事务所 (特殊普通合伙) 二〇二五年五月十四日 和信会计师事务所(特殊普通合伙) 关于对山东鲁抗医药股份有限公司 2024年年度报告的事后审核问询函的回复 和信综字(2025)第000229号 上海证券交易所: 根据贵所下发的《关于对山东鲁抗医药股份有限公司 2024年年度报告的事后审 核问询函》(上证公函〔2025〕第 0369 号)(以下简称"问询函")的要求,我们对 间询函中提及的事项进行了审慎核查。现回复如下: 一、关于土地收储收益的确认 公告显示,公司 2016年实施"退城进园",当地政府拟将公司南厂区及控股股 东五宗国有建设用地进行收储,收储补偿费约 3.6亿元,其中含控股股东补偿费 0.23 亿元。2020年公司顺利完成搬迁工作,搬迁完成时公司将相关土地、地上附着物净值 计入长期应收款。2024年6月,公司按约定完成土壤治理修复等工作,完成土地整体 移交。年报显示,土地收储收益 1.52亿元,公司一次性计入 2024年度损益,占当年 归母净利润的 24%。 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-022 — 1 — 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，山东鲁抗医药股份有限公司（以下简称 "公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司 联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 特此公告！ 2025 年 5 月 13 日 山东鲁抗医药股份有限公司 关于参加 2025 年山东辖区上市公司 ...

Core Viewpoint - Lu Kang Pharmaceutical has received approval from the National Medical Products Administration for the market entry of Celecoxib, marking a significant milestone after substantial R&D investment [1][5]. Group 1: Product Approval and Market Potential - Celecoxib, developed by Pfizer, is the first selective COX-2 inhibitor approved globally, used for treating conditions like osteoarthritis, rheumatoid arthritis, acute pain, and ankylosing spondylitis [5]. - In 2023, sales of Celecoxib capsules in China's major markets exceeded 800 million yuan, ranking among the top 8 products in the category of oral anti-inflammatory and anti-rheumatic drugs, with a projected growth of 5.05% in the first half of 2024 [5]. - The demand for Celecoxib raw materials in China has been increasing, with usage rising from 91.62 tons in 2022 to 109.7 tons in 2023, reflecting a year-on-year growth rate of 19.7% [5]. Group 2: Competitive Landscape and Company Strategy - There are currently 53 registered raw material drug numbers for Celecoxib in China, with 38 passing the review process, indicating a competitive market [5]. - Companies like Hengrui Medicine and CSPC Pharmaceutical have already secured bids in the third batch of national centralized procurement for Celecoxib capsules [5]. - Lu Kang Pharmaceutical has invested a total of 14.899 million yuan in the R&D of Celecoxib raw materials, positioning itself for future product quality control and cost management advantages [5][7]. Group 3: Company Performance and Market Response - Lu Kang Pharmaceutical has shown steady revenue growth, with projected revenue of 6.233 billion yuan in 2024, a year-on-year increase of 1.41%, and a net profit of 408 million yuan, up 59.02% [7]. - The company's stock price has increased by 8.16% year-to-date, closing at 10.33 yuan per share on May 8, 2023, despite a slight daily decline [7].

Group 1 - Dashi Intelligent signed a smart hospital project contract worth 58.12 million yuan with the First Affiliated Hospital of Bengbu Medical College and Bengbu Urban Construction Investment Development Co., Ltd. [1] - The project aims to create a comprehensive tumor specialty hospital integrating medical care, research, teaching, preventive health care, and rehabilitation, which is expected to positively impact the company's future performance [1] Group 2 - Huahong Company reported a net profit of 22.76 million yuan for Q1 2025, a year-on-year decrease of 89.73%, despite a revenue increase of 18.66% to 3.913 billion yuan [2] - The company specializes in the development and application of embedded/non-volatile memory, power devices, and other semiconductor technologies [2] Group 3 - Jindi Group announced a signed area of 214,000 square meters in April, a year-on-year decrease of 55.14%, with a signed amount of 2.78 billion yuan, down 55.45% [3] - The company focuses on real estate development and sales, commercial real estate, and property management [3] Group 4 - Jinlong Automobile reported a bus production of 4,361 units in April, a year-on-year decrease of 5.79%, with sales of 3,611 units, down 3.91% [4][5] - The company is engaged in the production and sales of bus products [5] Group 5 - Sanyou Medical established a joint venture with CGBio Co., Ltd. with a registered capital of 60 million yuan, focusing on innovative cell biological materials and regenerative medicine [6][7] - The company specializes in the research, production, and sales of orthopedic implant consumables [7] Group 6 - Jinzhi Technology won a bid for projects related to the State Grid with a total amount of 90.73 million yuan, accounting for 5.12% of the company's projected revenue for 2024 [9][10] - The company focuses on smart energy and smart city businesses [10] Group 7 - Pinggao Electric won multiple procurement projects from the State Grid, totaling approximately 1.751 billion yuan, which is 14.12% of the company's projected revenue for 2024 [10] - The company specializes in high-voltage switchgear and power engineering contracting [10] Group 8 - Luantang Pharmaceutical received approval for the raw material drug Celecoxib, which is a selective COX-2 inhibitor with fewer gastrointestinal side effects compared to traditional NSAIDs [11][12] - The company is involved in the research, production, and sales of pharmaceutical products [12] Group 9 - Dongjie Intelligent obtained seven patent certificates related to AGV and conveyor system technologies [13][14] - The company specializes in the research, design, manufacturing, installation, and debugging of intelligent logistics systems [14] Group 10 - XJH Holdings received a government subsidy of 8.69 million yuan, which accounts for 38.67% of the company's projected net profit for 2024 [15][16] - The company focuses on the recycling and dismantling of waste electrical products [16] Group 11 - Huaihua Pharmaceutical's subsidiary received approval for the clinical trial of HZ-J001 ointment for treating non-segmental vitiligo [17][19] - The company is engaged in the research, production, and sales of pharmaceutical products [19] Group 12 - ST Aonong reported a pig sales volume of 132,800 heads in April, a year-on-year decrease of 14.42%, while the stock of pigs increased by 15.06% [22][23] - The company is involved in feed, pig farming, food, and trade [23] Group 13 - Beibu Gulf Port reported a cargo throughput of 31.75 million tons in April, a year-on-year increase of 20.32% [24][25] - The company specializes in port loading, storage, and related services [25] Group 14 - Dongfang Iron Tower won a bid for State Grid projects totaling approximately 100 million yuan, which is 2.39% of the company's projected revenue for 2024 [26] - The company focuses on steel structures and related businesses [26] Group 15 - Huanxu Electronics reported a consolidated revenue of 4.641 billion yuan in April, a year-on-year increase of 0.72% [27] - The company provides design, manufacturing, and related services for brand customers [27] Group 16 - Jincheng Co. announced that part of its bank accounts has been frozen, involving approximately 32.97 million yuan due to contract disputes [28][29] - The company specializes in high-end intelligent equipment for photovoltaic and smart port sectors [29] Group 17 - NAIKE Equipment announced the departure of core technical personnel Wang Xiangguo [30][31] - The company focuses on semiconductor packaging equipment and related products [31] Group 18 - Jiaojian Co. won a construction project in Hefei with a bid amount of approximately 704 million yuan, covering residential buildings and related infrastructure [32][33] - The company specializes in infrastructure construction and related services [33] Group 19 - Hongyuan Green Energy plans to transfer a 27.07% stake in Inner Mongolia Xinyuan Silicon Material Technology Co., Ltd. for 1.245 billion yuan [34][35] - The company focuses on the research, production, and sales of aviation electromechanical products [35] Group 20 - Poly Development reported a signed amount of 24.622 billion yuan in April, a year-on-year decrease of 25.44% [46][48] - The company specializes in real estate development and sales [48]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025—021 山东鲁抗医药股份有限公司 关于塞来昔布获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）收到国家药品监督管 理局颁发的关于塞来昔布（以下简称"该药品"）的《化学原料药上市申请批准 通知书》（通知书编号： 2025YS00356），该药品批准上市申请。现将相关情 况公告如下： 一、药品证书基本信息 药品名称：塞来昔布 塞来昔布由辉瑞公司开发。 全球第一个上市的选择性环氧化酶-2 抑制剂， 隶属于解热镇痛抗炎药-非甾体抗炎（NSAID）药品类。与传统 NSAID 相比，塞 来昔布具备较低的消化道不良反应，且镇痛抗炎疗效确切。 经查询，国内现有塞来昔布原料药登记号 53 个，其中 38 个已通过审评。药 智网数据显示，国内塞来昔布原料药在 2022、2023 年的年度用量分别为 91.62 吨、109.70 吨。 截至本公告日，公司用于该药品研发投入累计约人民币 1489.9 ...

鲁抗医药（600789）公告，公司收到国家药品监督管理局颁发的关于塞来昔布的《化学原料药上市申请 批准通知书》，该药品批准上市申请。截至本公告日，公司用于该药品研发投入累计约人民币1489.90 万元。公司塞来昔布的获批，为公司提高市场竞争力提供有效助力，对公司的经营业绩产生积极影响。 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-019 山东鲁抗医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 29 日 (二)股东大会召开的地点：山东鲁抗医药股份有限公司高新园区 A1115 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 2,008 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 242,506,143 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 26.9850 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，董事长彭欣先生主持。本次会议以现场投票及 网络投票相结合的方式进行表决，会议的召集、召开和表决方式符合《 ...

证券代码:600789 证券简称:鲁抗医药 公告编号:2025-020 山东鲁抗医药股份有限公司 第十一届董事会第七次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（下称"公司"）十一届董事会第七次（临时） 会议于2025年4月29日下午4:00在公司高新园区A1115会议室召开。本次会议召开 的通知已于2025年4月22日以电子邮件方式发出。会议应出席董事9人，实际出席 董事9人。会议由彭欣先生主持，本次会议的召开符合《公司法》和《公司章程》 的规定，形成的决议合法、有效。经过认真讨论，审议并通过了如下议案： 一、《公司2025 年第一季度报告》 本议案已经公司董事会审计委员会审议通过，并同意将此项议案提交公司董 事会审议。 2025年4月30日 同意9 票，反对0 票，弃权0 票 二、《关于公司2024 年度环境、社会和治理（ESG）报告的议案》 具体内容详见公司同日刊登于上海证券交易所网站(www.sse.com.cn)的《山东 鲁抗医药股份有限公司2024年度环境、社会和 ...

北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年四月 中国北京市建国门外大街 1 号国贸写字楼 2 座 12-14 层 100004 12-14th Floor, China World Office 2, No.1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2024 年年度股东大会的法律意见书 致：山东鲁抗医药股份有限公司 根据《中华人民共和国律师法》《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东大会规则》（以 下简称"《股东大会规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》（以下简称"《规范运作指引》"）等法律、法规和规范性文件以及《山东鲁 抗医药股 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,673,699,598.01, a decrease of 6.95% compared to CNY 1,798,732,648.44 in the same period last year[4] - Net profit attributable to shareholders increased by 16.77% to CNY 78,597,649.89 from CNY 67,307,574.42 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 64,656,985.97, up 21.14% from CNY 53,371,705.45 in the same period last year[4] - Net profit for Q1 2025 increased to CNY 82,348,970.57, compared to CNY 70,966,706.12 in Q1 2024, representing a growth of 15.88%[18] - Total comprehensive income amounted to CNY 81,042,801.40, an increase from CNY 70,966,706.12 in the previous year, representing a growth of approximately 14.4%[19] Cash Flow - The net cash flow from operating activities decreased significantly by 83.50%, amounting to CNY 26,871,193.66 compared to CNY 162,849,287.26 in the previous year[4] - The net cash flow from operating activities for Q1 2025 was CNY 26,871,193.66, a significant decrease from CNY 162,849,287.26 in Q1 2024[22] - Cash inflow from operating activities totaled CNY 1,280,615,436.19, compared to CNY 1,322,433,200.60 in the same period last year, reflecting a decline of about 3.2%[22] - Cash outflow from operating activities was CNY 1,253,744,242.53, up from CNY 1,159,583,913.34, indicating an increase of approximately 8.1%[22] - The net cash flow from financing activities was negative CNY 4,003,435.49, an improvement from negative CNY 58,395,522.27 in the previous year[23] - The company experienced a cash outflow of CNY 605,003,435.49 from financing activities, compared to CNY 328,516,673.91 in Q1 2024, indicating an increase of about 84.2%[23] - The cash flow from investment activities was negative CNY 68,002,277.49, an improvement from negative CNY 94,536,998.13 in the same period last year[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,135,906,979.71, reflecting a slight increase of 0.42% from CNY 9,097,984,876.42 at the end of the previous year[5] - The company's total assets amounted to CNY 9,135,906,979.71, an increase from CNY 9,097,984,876.42 in the previous period[14] - Current liabilities totaled CNY 3,259,579,625.77, up from CNY 3,060,932,068.62, indicating an increase of 6.49%[14] - Non-current liabilities decreased to CNY 1,733,613,899.56 from CNY 1,975,482,433.06, a reduction of 12.26%[15] - The company's total equity rose to CNY 4,142,713,454.38, compared to CNY 4,061,570,374.74, marking an increase of 2.00%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 127,650[9] - The largest shareholder, Hualu Holding Group Co., Ltd., holds 20.6% of the shares, totaling 185,896,620 shares[9] Expenses - Total operating costs for Q1 2025 were CNY 1,603,575,969.64, down from CNY 1,738,362,575.97 in Q1 2024, reflecting a reduction of 7.73%[17] - Research and development expenses for Q1 2025 were CNY 68,836,886.27, down from CNY 80,658,203.12 in Q1 2024, a decrease of 14.66%[18] - The company reported a decrease in sales expenses to CNY 117,380,480.29 from CNY 201,910,852.00, a significant reduction of 41.76%[18] Earnings Per Share - The company reported a basic and diluted earnings per share of CNY 0.09, compared to CNY 0.08 in the previous year, marking a 12.5% increase[19] Government Subsidies - The company received government subsidies amounting to CNY 14,796,766.41, which are closely related to its normal business operations[6] Product Development - The company did not report any significant new product developments or market expansion strategies during this quarter[11]